WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018049263) COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/049263 International Application No.: PCT/US2017/050825
Publication Date: 15.03.2018 International Filing Date: 08.09.2017
IPC:
A61K 39/395 (2006.01) ,C07D 413/14 (2006.01) ,A61K 45/06 (2006.01) ,C07D 311/36 (2006.01) ,C07D 405/06 (2006.01) ,C07D 413/08 (2006.01) ,C07D 413/10 (2006.01) ,C07D 473/34 (2006.01) ,C07D 473/38 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
311
Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02
ortho- or peri-condensed with carbocyclic rings or ring systems
04
Benzo [b] pyrans, not hydrogenated in the carbocyclic ring
22
with oxygen or sulfur atoms directly attached in position 4
26
with aromatic rings attached in position 2 or 3
34
with aromatic rings attached in position 3 only
36
not hydrogenated in the hetero ring, e.g. isoflavones
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
08
linked by a carbon chain containing alicyclic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
473
Heterocyclic compounds containing purine ring systems
26
with an oxygen, sulfur, or nitrogen atom directly attached in position 2 or 6, but not in both
32
Nitrogen atom
34
attached in position 6, e.g. adenine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
473
Heterocyclic compounds containing purine ring systems
26
with an oxygen, sulfur, or nitrogen atom directly attached in position 2 or 6, but not in both
36
Sulfur atom
38
attached in position 6
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants: TG THERAPEUTICS, INC.[US/US]; 2 Gansevoort Street 9th Floor New York, New York 10014, US
RHIZEN PHARMACEUTICALS SA[CH/CH]; Fritz Courvoisier 40 2300 La Chaux de Fonds, CH
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES[FR/FR]; 3 Avenue des Tropiques 91940 Les Ulis, FR
Inventors: WEISS, Michael S.; US
MISKIN, Hari P.; US
SPORTELLI, Peter; US
Agent: STEFFE, Eric K.; US
BEZOS, Salvador M.; US
BODENSTEIN, Matthew S.; US
CALVO, Paul A.; US
CAMARCE, Christian A.; US
CIMBALA, Michelle A.; US
COLLER III, Richard D.; US
CONKLIN, Kyle E.; US
CORNWELL, David K.S.; US
COVERT, John M.; US
DURKIN, Tracy-Gene G.; US
EISENBERG, Jason D.; US
ELLISON, Eldora L.; US
ESMOND, Robert W.; US
FEATHERSTONE, Donald J.; US
FRUEAUF, Jeremiah B.; US
GOLDSTEIN, Jorge A.; US
GORDON, Lori A.; US
HELVEY, Jeffrey T.; US
HICKS, Ross; US
HOLOUBEK, Michelle K.; US
HOOVER, Kenley K.; US
JACKMAN, Peter A.; US
KIM, Ji-Eun; US
LEE, Michael Q.; US
LONGSWORTH, Gaby L.; US
MCGROARTY, John P.; US
MILLONIG, Robert C.; US
MUTSCHELKNAUS, Joseph; US
NANNENGA-COMBS, Bonnie; US
PICKARD, Byron L.; US
RAY, Michael B.; US
ROSE GILLENTINE, Marsha; US
RYGIEL, Mark W.; US
SHEA, JR., Timothy J.; US
SOKOHL, Robert E.; US
SPECHT, Michael D.; US
STERLING, Deborah A.; US
STERNE, Robert Greene; US
TUMINARO, Jonathan; US
WRIGHT, Jon E.; US
Priority Data:
62/385,72309.09.2016US
Title (EN) COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS
(FR) COMBINAISON D'UN ANTICORPS ANTI-CD20, D'UN INHIBITEUR DE PI3 KINASE-DELTA ET D'UN ANTICORPS ANTI-PD-1 OU ANTI-PD-L1 POUR LE TRAITEMENT DE CANCERS HÉMATOLOGIQUES
Abstract:
(EN) The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI3 kinase (PI3K)-delta (e.g., TGR-1202); (ii) at least one anti-CD20 antibody (e.g., ublituximab); and (iii) at least one anti-PD-1 antibody (e.g., pembrolizumab) or anti-PD-L1 antibody (e.g., atezolizumab). Treatment regimens are also provided.
(FR) La présente invention concerne des procédés et des kits pour traiter ou ralentir la progression d'une malignité hématologique, par administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace de : (i) au moins un inhibiteur de la PI3 kinase (PI3K)-delta (par exemple, TGR-1202); (ii) au moins un anticorps anti-CD20 (par exemple, ublituximab); et (iii) au moins un anticorps anti-PD-1 (par exemple, pembrolizumab) ou un anticorps anti-PD-L1 (par exemple, atezolizumab). L'invention concerne également des schémas thérapeutiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)